within Pharmacolibrary.Drugs.ATC.G;

model G03CA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 20 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,
    adminCount     = 1,
    Vd             = 0.0009,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01,
    Tlag           = 1200
  );

  annotation(Documentation(
    info ="<html><body><p>Estradiol is a potent estrogen steroid hormone involved in the development and maintenance of female reproductive tissues and secondary sexual characteristics. It is widely used as hormone replacement therapy in menopausal women, in contraception, and in transgender hormone therapy. Estradiol is approved and in clinical use today in various formulations.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult female volunteers aged 18-35 after a single oral dose of micronized estradiol.</p><h4>References</h4><ol><li><p>Doll, E, et al., &amp; Sarvaideo, JL (2022). Pharmacokinetics of Sublingual Versus Oral Estradiol in Transgender Women. <i>Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists</i> 28(3) 237–242. DOI:<a href=&quot;https://doi.org/10.1016/j.eprac.2021.11.081&quot;>10.1016/j.eprac.2021.11.081</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34781041/&quot;>https://pubmed.ncbi.nlm.nih.gov/34781041</a></p></li><li><p>Lobo, RA, &amp; Cassidenti, DL (1992). Pharmacokinetics of oral 17 beta-estradiol. <i>The Journal of reproductive medicine</i> 37(1) 77–84. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1548642/&quot;>https://pubmed.ncbi.nlm.nih.gov/1548642</a></p></li><li><p>Safer, JD (2022). Are the Pharmacokinetics of Sublingual Estradiol Superior or Inferior to Those of Oral Estradiol?. <i>Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists</i> 28(3) 351–352. DOI:<a href=&quot;https://doi.org/10.1016/j.eprac.2021.12.018&quot;>10.1016/j.eprac.2021.12.018</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35077906/&quot;>https://pubmed.ncbi.nlm.nih.gov/35077906</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G03CA03;
